Cargando…

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma

Despite recent advances in targeted therapies and immunotherapies metastatic melanoma remains only rarely curable. The objective of the present study was to identify novel therapeutic targets for metastatic melanoma. A library of 160 well-characterised and potent protein kinase inhibitors was screen...

Descripción completa

Detalles Bibliográficos
Autores principales:	MAHGOUB, T., EUSTACE, A.J., COLLINS, D.M., WALSH, N., O'DONOVAN, N., CROWN, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532220/ https://www.ncbi.nlm.nih.gov/pubmed/26201960 http://dx.doi.org/10.3892/ijo.2015.3097

Ejemplares similares

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
por: Eustace, Alex J, et al.
Publicado: (2008)

Predictive biomarkers for dasatinib treatment in melanoma
por: Eustace, Alex J., et al.
Publicado: (2014)

Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis
por: Walsh, N, et al.
Publicado: (2010)

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells
por: Glynn, Sharon A, et al.
Publicado: (2008)

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors
por: van der Noord, Vera E., et al.
Publicado: (2023)

A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin
por: Mukherjee, Nupur, et al.
Publicado: (2022)

Alterations in integrin expression modulates invasion of pancreatic cancer cells
por: Walsh, Naomi, et al.
Publicado: (2009)

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies
por: McDermott, Martina, et al.
Publicado: (2014)

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo
por: Ding, Xiaokai, et al.
Publicado: (2022)

Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16
por: Dixon-Clarke, Sarah E., et al.
Publicado: (2017)

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells
por: McDermott, Martina S. J., et al.
Publicado: (2019)

Development of CDK inhibitors as cancer therapeutics
por: Lane, D
Publicado: (2005)

CDK8: a new breast cancer target
por: Crown, John
Publicado: (2017)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
por: Garutti, Mattia, et al.
Publicado: (2021)

Targeted treatment of advanced and metastaticbreast cancer with lapatinib
por: Corkery, Brendan, et al.
Publicado: (2008)

A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy
por: McLaughlin, Ronan P., et al.
Publicado: (2019)

Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells
por: Margue, Christiane, et al.
Publicado: (2019)

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells
por: Gaule, Patricia, et al.
Publicado: (2019)

The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
por: Duffy, Michael J, et al.
Publicado: (2011)

Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer
por: Roche, Sandra, et al.
Publicado: (2023)

Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
por: Lelliott, Emily J., et al.
Publicado: (2022)

Regulatory functions of the Mediator kinases CDK8 and CDK19
por: Fant, Charli B., et al.
Publicado: (2018)

Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
por: Tavakolian, Shaian, et al.
Publicado: (2020)

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma
por: Brägelmann, Johannes, et al.
Publicado: (2017)

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2020)

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines
por: Coxon, Christopher R., et al.
Publicado: (2016)

Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models
por: Santra, Tapesh, et al.
Publicado: (2017)

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
por: Li, Qing, et al.
Publicado: (2022)

Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer
por: Walsh, Naomi, et al.
Publicado: (2020)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

The CDK-activating kinase Cdk7: Taking yes for an answer
por: Schachter, Miriam Merzel, et al.
Publicado: (2013)

Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors
por: Robert, Thomas, et al.
Publicado: (2020)

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
por: Buzzetti, Marta, et al.
Publicado: (2021)

WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells
por: Moiseeva, Tatiana N., et al.
Publicado: (2019)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
por: Azimi, Alireza, et al.
Publicado: (2018)

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
por: Ogata, Ryohei, et al.
Publicado: (2020)

JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21
por: Colleoni, B, et al.
Publicado: (2017)

CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss
por: Teitz, Tal, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2gfguoli62vtnijs76vuev298g